—
C+
C+ The full Closelook — membership. Open the C+ overview

Recursion Pharmaceuticals Inc (RXRX) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Recursion Pharmaceuticals Inc

RXRX in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Recursion Pharmaceuticals combines robotics, cell biology and data science to run drug discovery at industrial scale rather than through traditional lab-by-lab experiments. It has several candidates in early clinical trials, aimed at rare genetic disease, solid tumours, lymphoma and blood cancers, and works with larger drug makers such as Roche, Sanofi, Bayer and Takeda on parts of this pipeline. It is headquartered in Salt Lake City, Utah, and listed in the United States.
Where it sits in the stack
Recursion holds no seat in Closelook's Rubin index, the diary's map of the AI build-out. It sits instead in the broader healthcare and biotechnology sleeve of our universe, tracked as a user of AI-driven discovery tools rather than a supplier of AI infrastructure.
Who it is priced against
Closelook has not assigned Recursion a peer group. The competitor the market most often names alongside it is Exscientia, another company built around AI-driven drug discovery.
Why Closelook tracks it
Recursion carries no Closelook score and no index seat. It appears in the Pattern 03 report, which follows NVIDIA's strategic equity stakes as an early signal for the Rubin build-out, and in the Daily Pulse that tracks the resulting cohort; the most recent Daily Pulse shows Recursion had exited that tracked portfolio.
What the diary watches
The diary watches whether Recursion re-enters the Pattern 03 cohort if NVIDIA renews its investment, and whether clinical trial readouts from its pipeline draw attention back to the name.

Recursion Pharmaceuticals Inc (RXRX) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for RXRX, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

This name carries no Closelook score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against RXRX on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 50/100 · S&P 500 fund at 49, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-18
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 97th percentile of the window, +4.9% over 20 sessions. Factor regime → 2026-09-18
  • Sovereign pressure Index 0.07 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-18

FAQ · from the current data · as of 2026-09-19

Quick answers

What is Recursion Pharmaceuticals Inc (RXRX)?

Recursion Pharmaceuticals Inc trades as RXRX on the US exchange (US) in the Closelook research universe, as of the registry build of 2026-09-19.

Is RXRX in a Closelook index?

Not currently — Recursion Pharmaceuticals Inc is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-19.

Where does RXRX trade against its moving averages?

Recovery attempt under the 200-day: Trades +17.5% vs the 50-day and +6.2% vs the 200-day average, 46.7% below the 52-week high and +38.3% off the 52-week low. Computed from daily closes. As of 2026-09-18 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Recursion Pharmaceuticals Inc do?

Recursion Pharmaceuticals combines robotics, cell biology and data science to run drug discovery at industrial scale rather than through traditional lab-by-lab experiments. It has several candidates in early clinical trials, aimed at rare genetic disease, solid tumours, lymphoma and blood cancers, and works with larger drug makers such as Roche, Sanofi, Bayer and Takeda on parts of this pipeline. It is headquartered in Salt Lake City, Utah, and listed in the United States. Closelook has not assigned Recursion a peer group. The competitor the market most often names alongside it is Exscientia, another company built around AI-driven drug discovery.

Where does Recursion Pharmaceuticals Inc sit in the AI build-out?

Recursion holds no seat in Closelook's Rubin index, the diary's map of the AI build-out. It sits instead in the broader healthcare and biotechnology sleeve of our universe, tracked as a user of AI-driven discovery tools rather than a supplier of AI infrastructure. Recursion carries no Closelook score and no index seat. It appears in the Pattern 03 report, which follows NVIDIA's strategic equity stakes as an early signal for the Rubin build-out, and in the Daily Pulse that tracks the resulting cohort; the most recent Daily Pulse shows Recursion had exited that tracked portfolio.

Where has Closelook written about Recursion Pharmaceuticals Inc?

Recursion Pharmaceuticals Inc appears in 2 Closelook pieces, most recently Daily Pulse: Pattern 03 cohort — NVIDIA equity deployments as Rubin Build-Out leading indicator (2026-05-26); Report: Pattern 03 — NVIDIA Strategic Authority Investment (2026-05-12). What Closelook said most recently: Live cohort · 10 names Current portfolio after applying the 16-event timeline through 2026-05-26: COHR · CRWV · GLW · INTC · IREN · LITE · MRVL · NBIS · NOK · SNPS Hypothetical portfolio · $100k per signal Assumes a diary follower would… (Daily Pulse, 2026-05-26). The "Mentioned on Closelook" block on this page lists the long reads, the reference entries and the dailies that name it.

What does this page show?

A live price chart with SMA overlays and drawing tools for RXRX, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Mentioned on Closelook 2 pieces · newest: Daily Pulse, “Pattern 03 cohort — NVIDIA equity deployments as Rubin Build-Out leading indicator” (2026-05-26)

Mentioned on Closelook

Where RXRX appears in the diary — 2 pieces, newest first. Every link is our own writing.

Long reads

  • Pattern 03 — NVIDIA Strategic Authority InvestmentReport · 12 May 2026The 16-Event Timeline (2023-07-12 → 2026-05-12) 2024 2025 2026 RXRX 23-07 ARM 23-09 APLD 24-09 NBIS 24-12 MRVL 25-03 CRWV 25-03 INTC 25-09 NOK 25-10 SNPS 25-12 LITE COHR 26-03 IREN 26-05 GLW 26-05 exit RXRX exit APLD exit ARM Tier 1 …

Dailies

Related in the Closelook universe

same Closelook index seat first, then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.